Kaoru Shimokata

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

H. Saka, H. Ueoka, K. Shimokata, 2000, Cancer research.

Prognostic value of pleural effusion in patients with non-small cell lung cancer.

M. Ando, K. Shimokata, Y. Ando, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Continuous Infusion Versus Intermittent Short Infusion of Metoclopramide for Cisplatin‐Induced Acute Emesis

K. Shimokata, S. Yamori, H. Saito, 1994, American journal of clinical oncology.

Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene.

T. Tsukamoto, R. Ueda, K. Shimokata, 1993, Cancer research.

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.

H. Saka, K. Shimokata, T. Kamataki, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.

H. Saka, K. Shimokata, Y. Ando, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia.

K. Shimokata, Y. Sekido, K. Horibe, 2001, Pharmacogenetics.

Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and Irinotecan toxicity.

C. Kitagawa, K. Shimokata, Y. Sekido, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer

Y Ohno, M. Ando, K. Shimokata, 2001, British Journal of Cancer.

Cytokine content in pleural effusion. Comparison between tuberculous and carcinomatous pleurisy.

H. Saka, K. Shimokata, Y. Hasegawa, 1991, Chest.